Top 5 Small Cap Companies To Own In Right Now

Top 5 Small Cap Companies To Own In Right Now: Achillion Pharmaceuticals Inc.(ACHN)

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C; and the development of antibacterials for the treatment of resistant bacterial infections. Its drug candidates for the treatment of chronic HCV include ACH-1625, a protease inhibitor, which is in phase IIa clinical trial for the treatment of chronic HCV; ACH-2684, a pangenotypic protease inhibitor, which is in phase I clinical trial for the treatment of chronic HCV infection; and NS5A inhibitors for the treatment of chronic HCV infection, including ACH-2928, which is to enter a phase I clinical trial, as well as various additional NS5A inhibitors in preclinical development. Its pipeline of product candidates also includes ACH-702 and ACH-2881 for drug resistant bacterial infections; elvucitabine for HIV infection; and AC H-1095 for HCV infection. The company was founded in 1998 and is based in New Haven, Connecticut.

Advisors' Opinion:

• [By Roberto Pedone]

  An under-$10 biotechnology player that's starting to trend within range of triggering a big breakout trade is Achillion Pharmaceuticals (ACHN), discovers, develops and commercializes anti-infective drug therapies in the U.S. and internationally. This stock has been destroyed by the sellers so far in 2013, with shares down big by 66%.

  If you take a look at the chart for Achillion Pharmaceuticals, you'll notice that this stock has been trending sideways for the last month and change, with shares moving between $2.26 on the downside and $2.98 on the upside. This sideways trading pattern is occurring after shares of ACHN gapped down sharply in late September from $7.50 to! under $3 with heavy downside volume. Shares of ACHN are now starting to trend higher and move within range of triggering a big breakout trade above the upper-end of its sideways trading chart pattern.

  Traders should now look for long-biased trades in ACHN if it manages to break out above some near-term overhead resistance levels at $2.85 to $2.98 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 2.76 million shares. If that breakout triggers soon, then ACHN will set up to re-test or possibly take out its gap down day high from September at $3.62 a share. Any high-volume move above that level will then give ACHN a chance to re-fill some of its previous gap down zone that started at $7.50 a share.

  Traders can look to buy ACHN off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $2.44 to $2.26 a share. One can also buy ACHN off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By David Williamson]

  In this video, David Williamson describes how Achillion Pharmaceuticals (NASDAQ: ACHN  ) may challenge Gilead's (NASDAQ: GILD  ) dominance in the Hepatitis C drug market. Achillion is concluding phase 2 clinical trials of its oral interferon medication, and so far, things are looking good. If successful in phase 3 trials, Achillion could directly challenge Gilead's interferon medication. For investors, the success of Achillion's drug is attractive, but the potential for Achillion to be a takeover target is even more enticing. The company has a market cap of around $575 million and could easily be bought out by the likes of Bristol-Myers Squibb.

source from Top Stocks For 2015:http://www.topstocksblog.com/top-5-small-cap-com! panies-to! -own-in-right-now-2.html